Related Experiment Video
Updated: Aug 9, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Pharmacologic treatment of patients with arterial hypertension. Parameters to be considered when choosing a
Francisco Eugenio Rodríguez Castellanos1
1Departamento de Nefrología, Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D. F. rodcast61@hotmail.com
Insights
For mild hypertension, prioritize absolute cardiovascular risk over arbitrary blood pressure levels for treatment decisions. Consider patient factors and genetics for personalized antihypertensive therapy.
Area of Science:
- Cardiology
- Pharmacogenomics
- Internal Medicine
Context:
- Uncomplicated mild hypertension management guidelines.
- Need for individualized treatment strategies.
- Role of cardiovascular risk assessment.
Purpose:
- To guide clinical decisions in treating mild hypertension.
- To highlight factors influencing pharmacologic treatment initiation.
- To explore the impact of genetics on antihypertensive response.
Summary:
- Treatment decisions for mild hypertension should integrate absolute cardiovascular risk assessment, not solely blood pressure thresholds.
- Initiating pharmacologic therapy requires evaluating blood pressure levels, target organ damage, and co-existing risk factors.
- Personalized treatment considers demographics, comorbidities, quality of life, cost, drug interactions, and genetic predispositions for optimal antihypertensive selection and efficacy.
Impact:
- Facilitates evidence-based, patient-centered hypertension management.
- Enhances understanding of factors influencing antihypertensive drug effectiveness.
- Promotes the use of pharmacogenomics for predicting treatment responses and optimizing blood pressure control.
Abstract:
The decision to treat, or not treat, uncomplicated mild hypertension should be based on a formal estimate of absolute cardiovascular risk and not on an arbitrary blood pressure threshold. The decision to initiate pharmacologic treatment requires consideration of the degree of blood pressure elevation, the presence of target organ damage, and the presence of clinical cardiovascular disease or other risk factors. Special considerations include demographic characteristics, concomitant diseases that may be beneficially or adversely affected by the antihypertensive agent chosen, quality of life, cost, and use of other drugs that may lead to drug interactions. Diuretics, beta-blockers or ACE inhibitors may be used as first-step drug therapies for the treatment of uncomplicated hypertension. Genetic factors may contribute to interindividual differences in responses to antihypertensive drug therapy. Knowledge of polymorphic variation in these genes will help to predict individual patients' blood pressure responses to antihypertensive drug therapy and may also provide new insights into molecular mechanisms responsible for elevation of blood pressure.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Vasodilators
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension IV: Drug Therapy and Lifestyle Modifications

